Matt Field
Analyst · Cantor Fitzgerald. Please proceed
Thanks, Didier. Good afternoon, everyone, and thanks for joining us today. Our 2022 financial results for the fourth quarter and full-year reflect our disciplined and methodical approach to spending and resource prioritization. This approach and the support of our world class partners continues to serve us well and it has resulted in a strong balance sheet with $1.1 billion of cash and short-term marketable securities at the end of 2022. The progress that JoeBen and Didier highlighted reflects the hard work by the Joby team, which now numbers more than 1,400 globally. Over the course of last year, we grew our team approximately 30% with 90% of this hiring directly supporting engineering and manufacturing initiatives. Turning to our financial results in the fourth quarter of 2022, we incurred a net loss of $66.9 million or $0.11 per share, reflecting a loss from operations of $101.4 million partly offset by other income of $34.5 million. Our operating expenses included stock-based compensation expense of $17.2 million and depreciation and amortization of $6.6 million. Other income included the revaluation of our derivative liabilities worth $25.9 million and interest and other income, which rose to $8.1 million. Our net loss in the quarter was $72 million below our net income in the fourth quarter of 2021, largely reflecting higher operating expenses of $24 million, a lower favorable revaluation on derivative liabilities of $35 million and the non-recurrence of a one-time tax revaluation last year of almost $11 million. Our net loss compared with the third quarter of 2022 was $12 million lower reflecting higher operating expenses of $4 million more than offset by the favorable revaluation of our derivative liabilities totaling $13 million and higher interest income. Our fourth quarter adjusted EBITDA, which as a reminder, is a non-GAAP financial measure that we reconcile to net income in our shareholder letter was negative $77.6 million. This was $12.4 million greater than the fourth quarter of 2021, reflecting higher operating expenses outlined earlier and nearly flat compared with Q3 of 2022, reflecting the continued growth in personnel and R&D expenses to support our operations offset by the higher grant payments referenced earlier. We are well capitalized with $1.1 billion in cash and short-term marketable securities at the end of the fourth quarter. This includes Delta’s equity investment of $60 million received in October. Cash used in operating activities and purchases of property and equipment totaled $83.6 million for the quarter. Spending increased compared with the third quarter, reflecting higher capital expenditures, which included the acquisition of property and facilities in Santa Cruz to support Joby’s long-term growth for $25.5 million. In the fourth quarter, we also received the final disbursement from Summer Bio, our equity investment that discontinued operations last year. For full-year 2022, our net cash used in operating activities and purchase of property and equipment totaled $290.8 million. In last quarter's call, we highlighted that we expected our operating cash outflow to be under the low end of our spending guidance. Our reduced spending reflected the payment from Summer Bio, earlier than expected payments from the Department of Defense for contract deliverables, and lower spending across our operations. As we've explained in past quarters, our cash flow as referenced in our shareholder letter and which will be included in our 10-K, excludes cash held in our short-term investments. In the first quarter, we invested a substantial sum of the proceeds from our merger with the Reinvent Technology Partners. Therefore, our statement of cash flow shows a more sizable cash outflow reflecting this investment. As you have heard, we expect 2023 to be an exciting year as we shift from the definition phase to the implementation phase of type certification, including producing our company conforming aircraft and flying with a pilot on board. In addition, we are actively discussing potential locations for our Phase 1 manufacturing plant with multiple states. We expect to conclude these discussions in the first half of the year. As mentioned last quarter, we are also negotiating with the Department of Defense on our next contract, which is anticipated to include on base operations. We expect to be able to share more once we wrap up these discussions in the coming months. This is a key step forward for our initial operations expected in 2024 and it presents an opportunity to build operational experience in areas like training, maintenance and scheduling that are critical to our future success. At Joby, we're committed to maximizing the effectiveness of every dollar we spend. That's been our mantra since the early days of the business and it served us well. A great example of that approach is how we are timing our spending on manufacturing. We started with a low investment pilot line working with Toyota to develop and prove out scalable processes. We're effectively stress testing and refining our aircraft manufacturing before we scale and invest for higher volume production. It's the smart way to do things and that methodical, rational approach can be seen in each area of our operations. It allows us to de-risk our business model and keep each area of our business aligned, so we're only spending when we need to. In each case, we iterate, test and learn on a smaller scale with minimal investment prior to incurring more sizable cash outlays. In 2023, our key priorities continue to be progressing certification, ramping manufacturing and delivering on our commitments to our partners, including the Department of Defense and Delta as examples. To support these efforts, we expect our net cash used in operations and capital expenditure to fall between $360 million to $380 million. This projection reflects our assumptions for continued hiring in priority areas. Higher R&D expenditures including material to support certification and manufacturing, an increase in DoD-related deliverables related to R&D activities, lower capital expenditures, as well as the non-recurrence of the cash payments from Summer Bio. We look forward to sharing our progress with you all. As you've heard today, we have a lot happening this year to talk about. This concludes our prepared remarks. Operator, would you please instruct participants how to ask questions?